This document provides an overview of gastroretentive drug delivery systems (GRDDS). It discusses how GRDDS can prolong the gastric retention of dosage forms to target drug release in the stomach. It describes different approaches for GRDDS, including floating and non-floating systems. Floating drug delivery systems have a density less than gastric fluids and remain buoyant, while non-floating systems are retained through mechanisms like bioadhesion, unfolding designs, or high density. The document reviews the merits of GRDDS and factors affecting performance, as well as common evaluation methods and concludes that GRDDS have potential but also challenges to optimize drug absorption.
DRUG DELIVERY SYSTEM (gastro retentive drug delivery system)
Oral route is the most acceptable route for drug administration. Apart from conventional dosage forms several other forms were developed in order to enhance the drug delivery for prolonged time period and for delivering drug to a particular target site. Gastro-retentive drug delivery system (GRDDS) has gainned immense popularity in the field of oral drug delivery recently. it is a widely employed approach to retain the dosage form in the stomach for an extended period of time and release the drug slowly that can address many challenges associated with conventional oral delivery, including poor bioavailability. different innovative approaches are being applied to fabricate GRDDS. Gastroretentive drug delivery is an approach to prolong gastric residence time, there by targeting site-specific drugs release in the upper gastrointestinal tract (GIT) for local or systemic effects. It is obtained by retaining dosage form into stomach and by releasing the in controlled manner.
GASTRO RETENTIVE DRUG DELIVERY SYSTEM (GRDDS)JayeshRajput7
Gastro retentive drug delivery system which includes, principles concepts, advantages and disadvantages of GRDDS, Modulation of GI transit time, Approaches to extend GI transit, Buccal drug delivery systems, Principle of muco adhesion, advantages and disadvantages of GRDDS, Mechanism of drug permeation, Methods of formulation and its evaluations.
Gastro retentive drug delivery systems by shubham patilShubham Patil
General Discussion on Drug delivery System specially focused on Gastro-Retentive. I've covered various types and theories & understandably prepared this presentation for everyone who reads it.
DRUG DELIVERY SYSTEM (gastro retentive drug delivery system)
Oral route is the most acceptable route for drug administration. Apart from conventional dosage forms several other forms were developed in order to enhance the drug delivery for prolonged time period and for delivering drug to a particular target site. Gastro-retentive drug delivery system (GRDDS) has gainned immense popularity in the field of oral drug delivery recently. it is a widely employed approach to retain the dosage form in the stomach for an extended period of time and release the drug slowly that can address many challenges associated with conventional oral delivery, including poor bioavailability. different innovative approaches are being applied to fabricate GRDDS. Gastroretentive drug delivery is an approach to prolong gastric residence time, there by targeting site-specific drugs release in the upper gastrointestinal tract (GIT) for local or systemic effects. It is obtained by retaining dosage form into stomach and by releasing the in controlled manner.
GASTRO RETENTIVE DRUG DELIVERY SYSTEM (GRDDS)JayeshRajput7
Gastro retentive drug delivery system which includes, principles concepts, advantages and disadvantages of GRDDS, Modulation of GI transit time, Approaches to extend GI transit, Buccal drug delivery systems, Principle of muco adhesion, advantages and disadvantages of GRDDS, Mechanism of drug permeation, Methods of formulation and its evaluations.
Gastro retentive drug delivery systems by shubham patilShubham Patil
General Discussion on Drug delivery System specially focused on Gastro-Retentive. I've covered various types and theories & understandably prepared this presentation for everyone who reads it.
A REVIEW ON GASTRO RETENTIVE DRUG DELIVERY SYSTEM
SUBMITTED BY
MO SUHEB ANSARI
Assistant Professor
Department of Pharmaceutics
Faculty of pharmacy
Jahangirabad Institute of Technology Barabanki, Lucknow, Uttar Pradesh
Approaches Of Gastro-Retentive Drug Delivery System or GRDDSAkshayPatane
Approaches Of Gastro-Retentive Drug Delivery System
Includes:
Floating and Non-Floating drug delivery system with their subtypes
Like Non-effervescent system, Effervescent system, Raft forming system,
High Density system, Expandable system, Muco-adhesive system,
Super porous hydrogel system and Magnetic Systems, etc.
This presentation includes introduction, physiology of GIT, factors affecting GRDDS, Advantages and disadvantages, approaches to GRDDS and their mechanism, some of the marketed products using GRDDS mechanism.
GASTRO RETENTIVE DRUG DELIVERY SYSTEM, GRDDS, DRUG DELIVERY SYSTEM IN STOMACH...CHANDIGARH UNIVERSITY
Gastro-retentive drug delivery is an approach to prolong gastric residence time, thereby targeting site-specific drugs released in the upper gastrointestinal tract (GIT) for local or systemic effects. It is obtained by retaining dosage form in the stomach and by releasing them in a controlled manner. In this presentation, I have explained GRDDS and the different types of GRDDS. How drug works in stomach.
Gastro retentive drug delivery system (GRDDS)Ravish Yadav
gastro retentive drug delivery system topic include
1. introduction
2.advantages
3.technology
4.evaluation
5.disadvantages
6. matrix tablet
and other relative information regarding the topic
The term bioadhesive describes materials that bind to biological substrates, such as mucosal membranes and in bioadhesive drug delivery systems, the term bioadhesion is used to describe the bonding or adhesion between a synthetic or natural polymer and soft tissues such as epithelial cells. The bioadhesive drug delivery formulation highlights the fact that readily accessible sites are utilized with the eye, oral cavity and vegina being targeted. The GI tract and the nasal cavity have also been extensively examined as a site for bioadhesive drug delivery The prospect of writing this review article is to present comprehensive information related to mucoadhesion and mucoadhesive drug delivery systems. The article has highlighted all the aspects of mucoadhesive drug delivery systems which will be helpful for researches and academics. The article includes detailed information about mucosa the anatomy and physiology, the mechanisms and theories related to mucoadhesion, evaluation parameters of mucoadhesive dosage forms, mucoadhesive polymers and novel approaches related to mucoadhesive drug delivery system. The potential merits and demerits of mucoadhesive drug delivery as well as that of the polymers are also discussed. Vanitha G B | Mrs. S. Shyamla | Mr. S. Jeevanandham "Mucoadhesive Drug Delivery System" Published in International Journal of Trend in Scientific Research and Development (ijtsrd), ISSN: 2456-6470, Volume-6 | Issue-2 , February 2022, URL: https://www.ijtsrd.com/papers/ijtsrd49267.pdf Paper URL: https://www.ijtsrd.com/pharmacy/other/49267/mucoadhesive-drug-delivery-system/vanitha-g-b
Open access plays a pivotal role in propagating scientific information globally. It is completely user friendly and is open for all to access easily. Its salient features are, that it covers 50 worlds’s leading languages and have the facility of audio versions too. It invites every individual to share as well as explore scientific knowledge and research in the field of pharmaceutical sciences. It enhances scientific skills of the authors, readers, reviewers, editors and advisors by providing scientific credits. On whole it encourages each and everyone and attracts all towards the majestic world of science.
Floating drug delivery approach uses low-density systems that have sufficient buoyancy to flow over the
gastric contents and remains buoyant in the stomach without affecting the stomachic emptying rate for a
chronic period of time. This result is increased gastric retention time and better control of the fluctuations
in plasma drug concentration with a low risk of toxicity. Drugs, which are locally active in the stomach,
drugs having narrow absorption window and unstable in the intestine, and colonic environment, are the
potential drug candidates. The approach not only improves drug absorption but also minimizes the mucosal
irritation of drugs. As the approach requires a high fluid level in the stomach to float and work efficiently,
it makes the approach limited up to some extent. Many buoyant systems have been developed based on
granules, powders, capsules, tablets, laminated films, and hollow microspheres and few formulations have
been commercialized in the market at the present time. This review gives an overview of the approach of
floating drug delivery at present with sequential demystification thus enabling a greater understanding of
their role in medicine and drug delivery
A REVIEW ON GASTRO RETENTIVE DRUG DELIVERY SYSTEM
SUBMITTED BY
MO SUHEB ANSARI
Assistant Professor
Department of Pharmaceutics
Faculty of pharmacy
Jahangirabad Institute of Technology Barabanki, Lucknow, Uttar Pradesh
Approaches Of Gastro-Retentive Drug Delivery System or GRDDSAkshayPatane
Approaches Of Gastro-Retentive Drug Delivery System
Includes:
Floating and Non-Floating drug delivery system with their subtypes
Like Non-effervescent system, Effervescent system, Raft forming system,
High Density system, Expandable system, Muco-adhesive system,
Super porous hydrogel system and Magnetic Systems, etc.
This presentation includes introduction, physiology of GIT, factors affecting GRDDS, Advantages and disadvantages, approaches to GRDDS and their mechanism, some of the marketed products using GRDDS mechanism.
GASTRO RETENTIVE DRUG DELIVERY SYSTEM, GRDDS, DRUG DELIVERY SYSTEM IN STOMACH...CHANDIGARH UNIVERSITY
Gastro-retentive drug delivery is an approach to prolong gastric residence time, thereby targeting site-specific drugs released in the upper gastrointestinal tract (GIT) for local or systemic effects. It is obtained by retaining dosage form in the stomach and by releasing them in a controlled manner. In this presentation, I have explained GRDDS and the different types of GRDDS. How drug works in stomach.
Gastro retentive drug delivery system (GRDDS)Ravish Yadav
gastro retentive drug delivery system topic include
1. introduction
2.advantages
3.technology
4.evaluation
5.disadvantages
6. matrix tablet
and other relative information regarding the topic
The term bioadhesive describes materials that bind to biological substrates, such as mucosal membranes and in bioadhesive drug delivery systems, the term bioadhesion is used to describe the bonding or adhesion between a synthetic or natural polymer and soft tissues such as epithelial cells. The bioadhesive drug delivery formulation highlights the fact that readily accessible sites are utilized with the eye, oral cavity and vegina being targeted. The GI tract and the nasal cavity have also been extensively examined as a site for bioadhesive drug delivery The prospect of writing this review article is to present comprehensive information related to mucoadhesion and mucoadhesive drug delivery systems. The article has highlighted all the aspects of mucoadhesive drug delivery systems which will be helpful for researches and academics. The article includes detailed information about mucosa the anatomy and physiology, the mechanisms and theories related to mucoadhesion, evaluation parameters of mucoadhesive dosage forms, mucoadhesive polymers and novel approaches related to mucoadhesive drug delivery system. The potential merits and demerits of mucoadhesive drug delivery as well as that of the polymers are also discussed. Vanitha G B | Mrs. S. Shyamla | Mr. S. Jeevanandham "Mucoadhesive Drug Delivery System" Published in International Journal of Trend in Scientific Research and Development (ijtsrd), ISSN: 2456-6470, Volume-6 | Issue-2 , February 2022, URL: https://www.ijtsrd.com/papers/ijtsrd49267.pdf Paper URL: https://www.ijtsrd.com/pharmacy/other/49267/mucoadhesive-drug-delivery-system/vanitha-g-b
Open access plays a pivotal role in propagating scientific information globally. It is completely user friendly and is open for all to access easily. Its salient features are, that it covers 50 worlds’s leading languages and have the facility of audio versions too. It invites every individual to share as well as explore scientific knowledge and research in the field of pharmaceutical sciences. It enhances scientific skills of the authors, readers, reviewers, editors and advisors by providing scientific credits. On whole it encourages each and everyone and attracts all towards the majestic world of science.
Floating drug delivery approach uses low-density systems that have sufficient buoyancy to flow over the
gastric contents and remains buoyant in the stomach without affecting the stomachic emptying rate for a
chronic period of time. This result is increased gastric retention time and better control of the fluctuations
in plasma drug concentration with a low risk of toxicity. Drugs, which are locally active in the stomach,
drugs having narrow absorption window and unstable in the intestine, and colonic environment, are the
potential drug candidates. The approach not only improves drug absorption but also minimizes the mucosal
irritation of drugs. As the approach requires a high fluid level in the stomach to float and work efficiently,
it makes the approach limited up to some extent. Many buoyant systems have been developed based on
granules, powders, capsules, tablets, laminated films, and hollow microspheres and few formulations have
been commercialized in the market at the present time. This review gives an overview of the approach of
floating drug delivery at present with sequential demystification thus enabling a greater understanding of
their role in medicine and drug delivery
Leading the Way in Nephrology: Dr. David Greene's Work with Stem Cells for Ki...Dr. David Greene Arizona
As we watch Dr. Greene's continued efforts and research in Arizona, it's clear that stem cell therapy holds a promising key to unlocking new doors in the treatment of kidney disease. With each study and trial, we step closer to a world where kidney disease is no longer a life sentence but a treatable condition, thanks to pioneers like Dr. David Greene.
India Clinical Trials Market: Industry Size and Growth Trends [2030] Analyzed...Kumar Satyam
According to TechSci Research report, "India Clinical Trials Market- By Region, Competition, Forecast & Opportunities, 2030F," the India Clinical Trials Market was valued at USD 2.05 billion in 2024 and is projected to grow at a compound annual growth rate (CAGR) of 8.64% through 2030. The market is driven by a variety of factors, making India an attractive destination for pharmaceutical companies and researchers. India's vast and diverse patient population, cost-effective operational environment, and a large pool of skilled medical professionals contribute significantly to the market's growth. Additionally, increasing government support in streamlining regulations and the growing prevalence of lifestyle diseases further propel the clinical trials market.
Growing Prevalence of Lifestyle Diseases
The rising incidence of lifestyle diseases such as diabetes, cardiovascular diseases, and cancer is a major trend driving the clinical trials market in India. These conditions necessitate the development and testing of new treatment methods, creating a robust demand for clinical trials. The increasing burden of these diseases highlights the need for innovative therapies and underscores the importance of India as a key player in global clinical research.
Empowering ACOs: Leveraging Quality Management Tools for MIPS and BeyondHealth Catalyst
Join us as we delve into the crucial realm of quality reporting for MSSP (Medicare Shared Savings Program) Accountable Care Organizations (ACOs).
In this session, we will explore how a robust quality management solution can empower your organization to meet regulatory requirements and improve processes for MIPS reporting and internal quality programs. Learn how our MeasureAble application enables compliance and fosters continuous improvement.
The Importance of Community Nursing Care.pdfAD Healthcare
NDIS and Community 24/7 Nursing Care is a specific type of support that may be provided under the NDIS for individuals with complex medical needs who require ongoing nursing care in a community setting, such as their home or a supported accommodation facility.
Global launch of the Healthy Ageing and Prevention Index 2nd wave – alongside...ILC- UK
The Healthy Ageing and Prevention Index is an online tool created by ILC that ranks countries on six metrics including, life span, health span, work span, income, environmental performance, and happiness. The Index helps us understand how well countries have adapted to longevity and inform decision makers on what must be done to maximise the economic benefits that comes with living well for longer.
Alongside the 77th World Health Assembly in Geneva on 28 May 2024, we launched the second version of our Index, allowing us to track progress and give new insights into what needs to be done to keep populations healthier for longer.
The speakers included:
Professor Orazio Schillaci, Minister of Health, Italy
Dr Hans Groth, Chairman of the Board, World Demographic & Ageing Forum
Professor Ilona Kickbusch, Founder and Chair, Global Health Centre, Geneva Graduate Institute and co-chair, World Health Summit Council
Dr Natasha Azzopardi Muscat, Director, Country Health Policies and Systems Division, World Health Organisation EURO
Dr Marta Lomazzi, Executive Manager, World Federation of Public Health Associations
Dr Shyam Bishen, Head, Centre for Health and Healthcare and Member of the Executive Committee, World Economic Forum
Dr Karin Tegmark Wisell, Director General, Public Health Agency of Sweden
ICH Guidelines for Pharmacovigilance.pdfNEHA GUPTA
The "ICH Guidelines for Pharmacovigilance" PDF provides a comprehensive overview of the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) guidelines related to pharmacovigilance. These guidelines aim to ensure that drugs are safe and effective for patients by monitoring and assessing adverse effects, ensuring proper reporting systems, and improving risk management practices. The document is essential for professionals in the pharmaceutical industry, regulatory authorities, and healthcare providers, offering detailed procedures and standards for pharmacovigilance activities to enhance drug safety and protect public health.
CRISPR-Cas9, a revolutionary gene-editing tool, holds immense potential to reshape medicine, agriculture, and our understanding of life. But like any powerful tool, it comes with ethical considerations.
Unveiling CRISPR: This naturally occurring bacterial defense system (crRNA & Cas9 protein) fights viruses. Scientists repurposed it for precise gene editing (correction, deletion, insertion) by targeting specific DNA sequences.
The Promise: CRISPR offers exciting possibilities:
Gene Therapy: Correcting genetic diseases like cystic fibrosis.
Agriculture: Engineering crops resistant to pests and harsh environments.
Research: Studying gene function to unlock new knowledge.
The Peril: Ethical concerns demand attention:
Off-target Effects: Unintended DNA edits can have unforeseen consequences.
Eugenics: Misusing CRISPR for designer babies raises social and ethical questions.
Equity: High costs could limit access to this potentially life-saving technology.
The Path Forward: Responsible development is crucial:
International Collaboration: Clear guidelines are needed for research and human trials.
Public Education: Open discussions ensure informed decisions about CRISPR.
Prioritize Safety and Ethics: Safety and ethical principles must be paramount.
CRISPR offers a powerful tool for a better future, but responsible development and addressing ethical concerns are essential. By prioritizing safety, fostering open dialogue, and ensuring equitable access, we can harness CRISPR's power for the benefit of all. (2998 characters)
One of the most developed cities of India, the city of Chennai is the capital of Tamilnadu and many people from different parts of India come here to earn their bread and butter. Being a metropolitan, the city is filled with towering building and beaches but the sad part as with almost every Indian city
Antibiotic Stewardship by Anushri Srivastava.pptxAnushriSrivastav
Stewardship is the act of taking good care of something.
Antimicrobial stewardship is a coordinated program that promotes the appropriate use of antimicrobials (including antibiotics), improves patient outcomes, reduces microbial resistance, and decreases the spread of infections caused by multidrug-resistant organisms.
WHO launched the Global Antimicrobial Resistance and Use Surveillance System (GLASS) in 2015 to fill knowledge gaps and inform strategies at all levels.
ACCORDING TO apic.org,
Antimicrobial stewardship is a coordinated program that promotes the appropriate use of antimicrobials (including antibiotics), improves patient outcomes, reduces microbial resistance, and decreases the spread of infections caused by multidrug-resistant organisms.
ACCORDING TO pewtrusts.org,
Antibiotic stewardship refers to efforts in doctors’ offices, hospitals, long term care facilities, and other health care settings to ensure that antibiotics are used only when necessary and appropriate
According to WHO,
Antimicrobial stewardship is a systematic approach to educate and support health care professionals to follow evidence-based guidelines for prescribing and administering antimicrobials
In 1996, John McGowan and Dale Gerding first applied the term antimicrobial stewardship, where they suggested a causal association between antimicrobial agent use and resistance. They also focused on the urgency of large-scale controlled trials of antimicrobial-use regulation employing sophisticated epidemiologic methods, molecular typing, and precise resistance mechanism analysis.
Antimicrobial Stewardship(AMS) refers to the optimal selection, dosing, and duration of antimicrobial treatment resulting in the best clinical outcome with minimal side effects to the patients and minimal impact on subsequent resistance.
According to the 2019 report, in the US, more than 2.8 million antibiotic-resistant infections occur each year, and more than 35000 people die. In addition to this, it also mentioned that 223,900 cases of Clostridoides difficile occurred in 2017, of which 12800 people died. The report did not include viruses or parasites
VISION
Being proactive
Supporting optimal animal and human health
Exploring ways to reduce overall use of antimicrobials
Using the drugs that prevent and treat disease by killing microscopic organisms in a responsible way
GOAL
to prevent the generation and spread of antimicrobial resistance (AMR). Doing so will preserve the effectiveness of these drugs in animals and humans for years to come.
being to preserve human and animal health and the effectiveness of antimicrobial medications.
to implement a multidisciplinary approach in assembling a stewardship team to include an infectious disease physician, a clinical pharmacist with infectious diseases training, infection preventionist, and a close collaboration with the staff in the clinical microbiology laboratory
to prevent antimicrobial overuse, misuse and abuse.
to minimize the developme
1. AN OVERVIEW ON GASTRORETENTIVE
DRUG DELIVERY SYSTEM
V.KEERTHI
M.PHARMACY
[1stSEMESTER ]
2. INTRODUCTION :
Drug absorption in the gastrointestinal tract is a highly variable
procedure and prolonging gastric retention of the dosage form extends
the time for drug absorption. Gastro retentive drug delivery system is
one of such novel approaches to prolong gastric residence time,
thereby targeting site specific drug release in the stomach for local or
systemic effects. This approach is useful particularly for the drugs
which have narrow absorption window in the upper part of gastro
intestinal tract. Various approaches of gastro retentive drug delivery
system, such as floating and non-floating, have been discussed in this
review. This review also gives an overview of merits, demerits and
evaluation parameters of gastro retentive system
3. About 90% of all drugs used to produce systemic
effects are administered by oral route. Of the
drugs that are administered orally, solid oral
dosage forms represent the preferred class of
products. Tablets are the most common type of
solid dosage form in contemporary use which is
classified based on the drug release pattern, i.e.
conventional immediate release and modified
release The conventional instant release tablets
have many drawbacks including non-site
specific drug release. However, many drugs are
absorbed from specific sites and they require
release at that site only for better absorption
4. Drug absorption in the gastrointestinal tract is a highly variable
procedure and it depends upon the factors such as gastric emptying
process, gastrointestinal transit time of dosage forms, drug release from
the dosage form, and site of absorption of drugs. Drugs that are easily
absorbed from the gastro intestinal tract (GIT) and have short half lives
are eliminated quickly from the systemic circulation. Frequent dosing of
these drugs is required to achieve suitable therapeutic activity. Also, the
drugs which have a narrow absorption window (NAW) in the upper part
of GIT are not suitable for oral sustained release drug delivery system
Davis, in 1968 firstly described the concept of floating drug delivery
system after experiencing chocking in some persons while swallowing
pills. He removed this difficulty by providing the pills having density
less than 1 gm/ml so that the pills will float on the water surface. Since
then several approaches have been proposed for ideal floating delivery
devices
5. MERITS OF GASTRORETENTIVE DRUG DELIVERY
SYSTEM (GRDDS)
The GRDDS has the following advantages:
Enhanced bioavailability: The bioavailability of the drugs
having absorption in the upper part of the GIT like
riboflavin, levodopa has tremendously been increased than
that of the conventional dosage forms
Sustained drug delivery and reduced frequency of dosing.
This improves patient compliance.
Targeted delivery of the drug at the upper part of the GIT
making it suitable for the local treatment of the disease of
the region eg; antacids, anti-ulcer drugs, antibacterial for H.
pylori infection
6. Suitable for the drugs which have pH dependent absorption
from stomach eg., Furosemide, Captopril, Diazepam,
Verapamil, Cefpodoxime proxetil.
Suitable for the drugs which degrade in the intestine or
column [16] eg., Ranitidine hydrochloride.
Drug level fluctuation is not observed and maintains the
optimal therapeutic plasma and tissue concentrations over
prolonged time period. This avoids sub-therapeutics as well
as toxic concentration and minimizes the risk of failure of the
medical treatment and undesirable side effects
7. LIMITATIONS OF GRDDS
Not suitable for the drugs which are not stable in acidic environment.
•Not suitable for the drugs which are absorbed better in the lower part
of GIT.
•Difficulty to attain the desired outcome and problem of the dose
dumping.
•Gastric retention is influenced by many factors like gastric motility,
pH and presence of food. Hence, the dosage form must be able to
withstand the grinding and churning force of peristaltic wave of
stomach.
•Poor in vitro and in vivo correlation.
•Higher cost of formulation.
•Retrieval of drug is difficult in case of toxicity, poisoning or
hypersensitivity reaction
8. FACTORS AFFECTING THE GRDDS
The factors that affect the gastric emptying and hence the gastric
retention of the drugs includes:
Fasting or fed state of the stomach: During the fasting state an
inter-digestive series of electrical events take place, which cycle
both through stomach and intestine every 2 to 3 hours. In the fed
state this cycle is delayed and hence the gastric emptying rate is
slowed.
Density, size and shape of the dosage form
Intake of food with drugs: the nature of the food, calorie
content and its frequency of intake have considerable effect on
the retention of drugs in stomach.
Concomitant administration of drugs such as ant cholinergic
agents e.g., atropine, propantheline and opiates delay the gastric
emptying while the prokinetic agents like metoclopramide and
cisapride enhance the gastric emptying process
9. Biological factors such as gender, posture, age, sleep, body mass
index, physical activity and disease states e.g. diabetes and Crohn’s
disease
DIFFERENT APPROACHES OF THE GRDDS
Different approaches have been pursued to increase the retention
of oral dosage forms in the stomach. Some are formulated as single
component whereas others are formulated as multi-component
dosage forms. GRDDS can be broadly categorized into floating
and non-floating system.
A. Non-floating system: These gastro retentive drug delivery
systems do not float in the stomach however they remain retained
there by different mechanisms. Non-floating system is further
divided into:
10. a. High density (sinking) drug delivery system
b. Bioadhsive or mucoadhesive system
c. Magnetic system
d. Unfoldable system
B. Floating drug delivery system (FDDS): In contrast to the high density drug
delivery system, floating systems have density less than the gastric content so
the system remain buoyant in the stomach for a prolonged period of time
without affecting the gastric contents. Floating drug delivery systems are also
known as low density system. Figure 1 shows the mechanism of floating of this
system
Figure 1 The mechanism of floating
system
11. Floating drug delivery system can be divided into:
a. Effervescent system
b. Noneffervescent system
i. Hydrodynamically balanced system
ii. Microbaloons or hollow microspheres
iii. Alginate beads
iv. Microporous compartment
A. Non-floating system
a. High Density (Sinking) Drug Delivery System
In this approach formulations are prepared by coating drug on a heavy
core or mixed with inert materials such as iron powder, barium sulfate,
zinc oxide and titanium oxide so that the density of the formulation
exceeds the density of the normal gastric content [29]. These materials
increase the density up to 1.5-2.4 gm/cm3. Depending on density, the GI
transit time of pellets can be extended from an average of 5.8 to 25
hours.
12. b. Bioadhsive or mucoadhesive system ;
The gastric retention time is extended by adhering the bioadhesive system
to gastric mucosa membrane .The adherence of the delivery system to the
gastric wall increases residence time thereby improving bioabailability.
The chemicals used for the mucoadhesion purpose include polycarbophil,
carbopol, lectin, chitosan, carboxy methyl cellulose, gliadin etc. Novel
adhesive material derived from fimbrae of bacteria or its synthetic
analogues have also been tried for the attachment to the gut.
c. Magnetic system
In this system, the dosage form contains a small magnet and another
magnet is placed on the abdomen over the position of the stomach. The
external magnet should be placed with a degree of precision which may
decrease the patient compliance
13. d. Unfoldable system
The drug delivery system unfolds and increases in size and it
remains lodged at sphincter avoiding its exit from the stomach).
For this the system should be small enough to Chhetri et al.,
Vol.10, No.I, November, 2014, pp 90-103 95
be swallowed but unfold itself when it comes in contact with
gastric fluid, and after a certain period of time its size should
become small so that it will be easily evacuated. The unfoldable
systems are made up of different biodegradable polymers.
14. B. Floating Drug Delivery System
a. Effervescent System
This system consists of the swellable polymers like
Chitosan and effervescent substance like sodium
bicarbonate, disodium glycine carbonate, cytroglycine,
citric acid and tartaric acid. When the system comes in
contact with gastric fluid, it releases carbon dioxide
causing the formulation to float in the stomach .
The optimal ratio of citric acid and sodium bicarbonate
for gas generation is reported to be 0.76:1 [9]. This
system is further divided as single unit matrix tablets or
multiple unit pills. Single unit matrix tablet may be single
or multilayer type.
15. b. Non-effervescent system ;
In this system, gel forming or highly swellable cellulose type
hydrocolloids, polysaccharides, and matrix forming polymers such as
polycarbonate, polyacrylate, polymethacrylate and polystyrene are used.
After oral administration this dosage form swells in contact with gastric
fluids and attains a bulk density of less than 1.
The dosage form swells significantly to several times of original volume
upon contact with gastric fluid, the gastric contraction pushes the dosage
form to the pylorus but due to larger size of the dosage form, the
contractions slips over the surface of the system, due to which the dosage
form pushes back into the stomach.
16. Non-effervescent system can be further divided in to:
hydrodynamically balanced system, microbaloons,
alginate beads, and micro porous compartment .
Hydrodynamically balanced system: The
hydrodynamically balanced system (HBS) was first
designed by Sheth and Tossounian .HBS contains drug
with gel-forming hydrocolloids meant to remain
buoyant on the stomach content. This system contains
one or more gel forming cellulose type hydrocolloid
e.g., hydroxypropyl methyl cellulose, ethyl cellulose,
hydroxypropyl cellulose, agar, carrageen or alginic acid.
It also contains matrix forming polymers such as
polycarbophil, polyacrylate and polystyrene.
17. Microbaloons or hollow microspheres: Hollow
microspheres (microballoons), loaded with drug in
their outer polymer shells, are prepared by emulsion-
solvent diffusion method. The steps involved in this
method are summarized in figure 9. The ethanol:
dichloromethane solution (1:1) and an acrylic polymer
are poured into an agitated aqueous solution of
polyvinyl alcohol at 40°C.
The microballoons float continuously over the surface
of acidic dissolution media containing surfactant for
more than 12 hours .
18. iii. Alginate beads: Freeze dried calcium alginates have
been used to develop multi unit floating dosage forms.
By dropping sodium alginate solution into aqueous
solution of calcium chloride spherical beads of about 2.5
mm diameter can be prepared. These beads are separated
and air dried. This results in the formation of a porous
system which remains buoyant in the stomach.
iv. Microporous compartment: In this system, drug
reservoir is encapsulated inside a microporous
compartment having pores along its top and bottom
walls. The floatation chamber containing entrapped air
causes the delivery system to float over the gastric
content. Gastric fluid enters through the aperture,
dissolves the drug and carries the dissolved drug in
stomach and proximal part of the small intestine for
absorption.
19. EVALUATION PARAMETERS OF GRDDS
Evaluation parameters of GRDDS generally include:
1. Drug-excipient interaction:
It is done by using FTIR and HPLC. Appearance of a
new peak and/or disappearance of original drug or
excipient peaks indicate the drug excipient interaction.
2. Floating lag time
It is the time taken to emerge tablet onto the surface after
it is kept in to the dissolution medium. It is measured in
minutes or seconds.
3. In vitro drug release and duration of floating
It is determined by using USP II apparatus (paddle)
stirring at a speed of 50 or 100 rpm at 37±2OC in
simulated gastric fluid of pH 1.2. Aliquots of the samples
are collected and analyzed for the drug content.
20. . The time for which the drug remains floating on the surface of
the medium is the duration of the floating time.
4. In vivo evaluation of gastric retention
Analysis of the position of the dosage form in the GIT involves
an imaging technique such as γ-scintigraphy and X-ray.
In γ-scintigraphy, a small amount of stable isotope is
compounded in the dosage forms during its preparation. The
inclusion of a γ-emitting radio-nuclide in a formulation allows
indirect external observation using a γ-camera or scinti scanner.
For x-ray, barium sulfate is used as a contrast medium. It helps
to locate dosage form in the GIT by which one can predict and
correlate the gastric emptying time and the passage of dosage
form.
21. 5. Water uptake study: It is done by immersing the dosage form in simulated
gastric fluid at 37OC and determining the dimensional changes, such as
diameter and thickness, at regular interval of time. After the stipulated time
the swollen tablets are weighed and water uptake is measured in the terms of
percentage weight gain, as given:
WU= (Wt-Wo) X100/Wo; in which, Wt and Wo are the weight of the tablet
after time t and initially, respectively .
The tablets are also evaluated for hardness, friability, weight variation etc.
which are applicable for conventional instant release tablets. For the multiple
unit dosage forms like microsphere following tests are also essential apart
from the above tests:
Morphological and dimensional analysis: It is done with the aid of scanning
electron microscopy and optical microscope.
Percentage yield of microsphere.
Entrapment efficiency: The drug is extracted by suitable method and
analyzed to find out the amount of drug present.
22. CONCLUSION
Gastro retentive drug delivery technologies have been
extensively explored in recent years. GRDDS has the
potential to enable many drugs to provide less frequent
dosing and remains undoubtedly beneficial for the drugs
in the stomach and/or upper part of the intestine.
However, there are many obstacles that need to be
overcome to obtain the maximum benefit of the system.
Despite this many researchers are working towards the
best utilization of this technique, some with success and
others with failure due to unpredictability of the human
GIT. Thus to formulate a successful GRDDS, it is
necessary to take into consideration the physiological
event in the GIT, selection of correct combinations of
drugs and excipients and design appropriate formulation
strategies.
23. REFERENCES
[1] Lachman L, Liberman HA & Kanig JL, The theory and practice of
industrial pharmacy, Lea &Febiger, Philadelphia, (1986) 293, ISBN 0-8121-
0977-5.
[2] Aulton M, Aulton’s Pharmaceutics: The design and manufacture of
medicines, Churchill Livingstone, London, (2007) 397, ISBN 0-443-055173.
[3] Niranjanbhai BD, Mahendrakumar VN, Surendran CS, HSV &UMU,
Advances in GRDDS: Raft forming system a review, Journal of Drug
Delivery & Therapeutics, 2 (2012) 123.
[4] Strebeul A, Siepmann J & Bodmeier R, Gastro retentive drug delivery
system, Expert Opin Drug Deliv, 3 (2006) 217.
[5] Bardonnet PL, Faivre V, Pugh WJ, Piffaretti JC & Falson F,
Gastroretentive dosage forms: overview and special case of Helicobacter
pylori, J Control Release, 111 (2006) 1.